← All stocks

Nuvectis Pharma, Inc.

NVCT Net buying
CIK 0001875558 #2767 in the set updated 17 Sep 2026
Bought (12 mo)
$2.29M
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
+$2.29M
+$2.29M against sales at will

By person

9 insiders · 8 transactions
28.4×

Ron Bentsur holds 28.4 times base salary in stock. $73.77M of shares against $2.59M in salary for 2025.

Salary from the company's own proxy. The shares are what Ron Bentsur last reported holding, valued at $20.00, the price Common Stock was last bought or sold at on the open market here, on 30 Jun 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Mosseri Marlio Charles
10% owner
$1.87M (4)
+$1.87M
5,798,576
17.80%
$115.97M
+10.5%
BENTSUR RON
Chairman & CEO
$278.60K (2)
+$278.60K
3,688,424
11.32%
$73.77M
+13.6%
Sanchez Juan
Director
$75.27K (1)
+$75.27K
113,380
0.3480%
$2.27M
+220.5%
Kaplan Matthew L.
Director
$64.24K (1)
+$64.24K
159,760
0.4903%
$3.20M
+90.7%
Poradosu Enrique
Chief Science & Business Off
1,806,319
5.54%
$36.13M
+20.1%
Shemesh Shay
Chief Dev. & Ops. Officer
1,793,068
5.50%
$35.86M
+20.1%
Carson Michael J.
Vice President, Finance
230,118
0.7063%
$4.60M
+153.8%
Hoberman Kenneth
Director
168,140
0.5161%
$3.36M
+63.0%
Oliviero James F III
Director
122,828
0.3770%
$2.46M
+112.4%
Insider
Date
Role
Action
Shares
Price
Amount
BENTSUR RON
30 Jun 2026
Chairman & CEO
Buy
12,500
$20.00
$250.00K
Mosseri Marlio Charles
30 Jun 2026
10% owner
Buy indirect
50,000
$18.32
$916.00K
Kaplan Matthew L.
5 Nov 2025
Director
Buy
11,000
$5.84
$64.24K
Sanchez Juan
5 Nov 2025
Director
Buy
13,000
$5.79
$75.27K
BENTSUR RON
5 Nov 2025
Chairman & CEO
Buy
5,000
$5.72
$28.60K
Mosseri Marlio Charles
27 Oct 2025
10% owner
Buy indirect
72,836
$6.28
$457.41K
Mosseri Marlio Charles
24 Oct 2025
10% owner
Buy indirect
35,034
$6.15
$215.46K
Mosseri Marlio Charles
23 Oct 2025
10% owner
Buy indirect
46,900
$6.06
$284.21K

What was left out

Form 4 filings counted 16
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 711,200
History held since 8 Feb 2022